This template was built with Webflow's free Prospero UI Kit. Learn more
If you have just received a genetic report mentioning SCN2A haploinsufficiency, you may be staring at a word that did not exist in your vocabulary a week ago. It can feel both clinical and frightening at the same time. The good news is that the term itself describes something specific and understandable, and once you can picture what it means, the rest of your child's diagnosis starts to make more sense.
This guide breaks down what SCN2A haploinsufficiency is, how it affects the brain, what symptoms families commonly see, and where research is heading. It is written for caregivers — not for clinicians or scientists — though we have grounded every explanation in the current medical literature.
Every person inherits two copies of most genes — one from each biological parent. Haploinsufficiency is a genetic term meaning that one of those two copies is not working properly, and the single working copy alone is not enough to carry out the gene's full job.
In SCN2A haploinsufficiency, a child is born with one normally functioning copy of the SCN2A gene and a second copy that does not fully function as expected. In practical terms, this means children typically produce substantially reduced functional Nav1.2 protein, often approximating the effect of having only one working copy of the gene. The exact amount can vary depending on the specific variant, but the result is similar: less Nav1.2 than the brain expects.
This is why doctors and researchers sometimes call SCN2A haploinsufficiency a dosage problem. In many cases, the remaining copy functions relatively normally on its own, but the total amount of Nav1.2 produced is still insufficient for typical brain development and signaling.
The SCN2A gene gives the body the instructions to build a protein called Nav1.2 — a voltage-gated sodium channel. Sodium channels are tiny gates on the surface of brain cells that open and close to let charged particles flow in and out. That flow is how brain cells generate the electrical signals they use to talk to one another.
Nav1.2 is especially important early in life. In the first years of brain development, it helps young excitatory neurons fire properly and form connections. As development progresses, a related channel called Nav1.6 becomes increasingly important at the axon initial segment for sustaining high-frequency firing — but Nav1.2 continues to play a critical role in the dendrites, the branch-like structures where neurons receive signals from other cells. That ongoing dendritic role is one reason SCN2A is essential at every stage of life, not just infancy.
These two terms are closely related and often appear together in genetic reports, which can be confusing.
- Loss-of-function (LOF) describes what a mutation does to the channel — it reduces or eliminates how well that channel works.
- Haploinsufficiency describes the consequence — having only one functional copy is not enough for normal brain function.
Most cases of SCN2A haploinsufficiency are caused by loss-of-function mutations, including protein-truncating variants that prevent one copy of the gene from making a working channel at all. So while every haploinsufficiency case is a loss-of-function situation, not every loss-of-function variant produces classic haploinsufficiency. Some LOF variants make a partially working channel rather than no channel at all.
This distinction matters because SCN2A variants are generally grouped into three functional categories: gain-of-function (GOF), loss-of-function (LOF), and mixed function. SCN2A haploinsufficiency is generally considered part of the loss-of-function spectrum. The mutation type matters enormously for symptoms, prognosis, and especially treatment.
With substantially reduced Nav1.2 function available, certain brain cells — particularly excitatory pyramidal neurons in the cortex — cannot fire and integrate signals as efficiently as they should. Research published in Nature in 2025 by the laboratories of Kevin Bender and Nadav Ahituv at UCSF described how this reduction disrupts both the ability of these neurons to fire properly and the connections they form with their neighbors.
In simpler terms: the wiring of the brain is built and tuned through experience, and Nav1.2 helps neurons participate in that tuning. When the protein is reduced, those connections form less reliably, and the brain has a harder time learning to process information the way it typically would.
SCN2A haploinsufficiency can look very different from one child to the next. Some children have a strong autism profile with no seizures; others develop epilepsy, often later in infancy or childhood; some have significant intellectual disability while others have milder learning differences. Reviews in Brain and Genetics in Medicine emphasize that this variability is the rule, not the exception.
Many children with SCN2A haploinsufficiency are diagnosed with autism spectrum disorder (ASD), intellectual disability, or global developmental delay. SCN2A is considered one of the highest-confidence neurodevelopmental and autism-associated genes identified through large-scale exome sequencing studies.
Speech and language delays, social communication differences, sensory processing differences, and challenges with flexible thinking and decision-making are commonly reported by families and described in the clinical literature.
When seizures occur in children with loss-of-function SCN2A variants, they typically begin after the first three months of life — often in later infancy or childhood. This is in contrast to gain-of-function SCN2A variants, which usually cause seizures within the first weeks after birth. Some children with SCN2A haploinsufficiency never develop seizures at all.
Families and clinicians have described additional features in some children, including low muscle tone (hypotonia), coordination challenges, sensory hypersensitivity, sleep disruption, and gastrointestinal issues. These are not universal — every child's profile is different — but they are part of the broader picture clinicians watch for.
SCN2A haploinsufficiency is diagnosed through genetic testing — typically a panel for epilepsy or neurodevelopmental disorders, whole exome sequencing, or whole genome sequencing. The test report will name the specific variant found in SCN2A and usually classify it (for example, as a protein-truncating or loss-of-function variant).
The vast majority of SCN2A variants causing haploinsufficiency are de novo, meaning they arose newly in the child and were not inherited from either parent. This is something many families need to hear explicitly, because parental guilt is common and unwarranted. A de novo mutation is no one's fault — it is not the result of anything a parent did or did not do during pregnancy, and it does not reflect family history. Genetic counselors can be a valuable resource for understanding what a specific variant means for your family.
If you want to connect with other families navigating a similar diagnosis or contribute to natural history data, you can join the SCN2A community through the SCN2A Foundation.
Knowing whether a child's SCN2A variant causes loss of function (including haploinsufficiency), gain of function, or mixed function is one of the most important pieces of information a treating neurologist can have. The same gene can drive very different conditions depending on how the channel is affected, and the right treatment direction can differ accordingly.
Sodium channel blockers are a class of seizure medications that reduce sodium channel activity. For children with gain-of-function SCN2A variants — where the channel is overactive — these medications can be very helpful. For children with loss-of-function variants and SCN2A haploinsufficiency, the channel is already underactive, and blocking it further may worsen symptoms or provide limited benefit in some individuals — though treatment responses can vary significantly depending on circuitry, the specific epilepsy phenotype, and developmental timing.
This is not a decision for families to navigate alone. All seizure medication decisions should be made with a neurologist experienced in SCN2A-related disorders, ideally with the genetic test report in hand.
Because haploinsufficiency is fundamentally a dosage problem, it is also a particularly attractive target for new precision therapies. The therapeutic logic is straightforward: if there is one healthy gene copy already in place, the goal is to help that copy work harder — bringing the total amount of Nav1.2 protein closer to normal levels.
In September 2025, researchers led by Tamura, Nelson, and Spratt at UCSF — under the labs of Kevin Bender and Nadav Ahituv — published a landmark study in Nature demonstrating that CRISPR activation (CRISPRa) — a gene-editing tool that turns up the volume on existing genes without altering DNA — could rescue several disease-related deficits in mouse models of SCN2A haploinsufficiency. Importantly, the rescue worked even when treatment was given in adolescent mice, though it remains unknown how these findings will translate to human developmental windows. The study also showed CRISPRa rescued excitability in human stem-cell-derived neurons.
This work is preclinical — it has not yet been tested in humans, and the path from a mouse study to an approved therapy is long and uncertain. But it represents one of the strongest signals yet that SCN2A haploinsufficiency may be addressable at its root cause. You can follow the latest SCN2A research and emerging therapeutic pipelines through the Foundation's research updates.
A diagnosis of SCN2A haploinsufficiency does not define your child, and it does not write the ending to their story. Children with this condition are growing, learning, and surprising the people around them every day, and the science aimed at changing what is possible for them is moving faster now than at any point in the past.
Every family navigating an SCN2A diagnosis deserves answers, community, and continued progress. Continued research progress depends on sustained community support, advocacy, and funding. You can help by joining the SCN2A patient registry to add your child's data to the natural history record, and by making a donation to fund the research and resources that move this work forward.
This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Tamura S, Nelson AD, Spratt PWE, et al. CRISPR activation for SCN2A-related neurodevelopmental disorders. Nature. 2025;646(8086):983–991. Published online September 17, 2025. doi:10.1038/s41586-025-09522-w. https://www.nature.com/articles/s41586-025-09522-w
Berg AT, Thompson CH, Myers LS, et al. Expanded clinical phenotype spectrum correlates with variant function in SCN2A-related disorders. Brain. 2024;147(8):2761–2774. doi:10.1093/brain/awae125. https://academic.oup.com/brain/article/147/8/2761/7656659
Crawford K, Xian J, Helbig KL, et al. Computational analysis of 10,860 phenotypic annotations in individuals with SCN2A-related disorders. Genetics in Medicine. 2021. https://www.nature.com/articles/s41436-021-01120-1
Wolff M, Brunklaus A, Zuberi SM. Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond. Epilepsia. 2019;60(S3):S59–S67. https://onlinelibrary.wiley.com/doi/10.1111/epi.16336
Simons Searchlight. SCN2A-Related Syndrome Gene Guide. https://www.simonssearchlight.org/gene-guide/scn2a-2/
UCSF News. Can CRISPR Fix a Childhood Brain Disorder? September 2025. https://www.ucsf.edu/news/2025/09/430716/can-crispr-fix-childhood-brain-disorder
OMIM. SCN2A — Sodium Channel, Voltage-Gated, Type II, Alpha Subunit. https://www.omim.org/entry/182390
Spratt PWE, Ben-Shalom R, Keeshen CM, et al. The autism-associated gene Scn2a contributes to dendritic excitability and synaptic function in the prefrontal cortex. Neuron. 2019;103(4):673–685. https://pubmed.ncbi.nlm.nih.gov/31230762/
Share
If you have just received a genetic report mentioning SCN2A haploinsufficiency, you may be staring at a word that did not exist in your vocabulary a week ago. It can feel both clinical and frightening at the same time. The good news is that the term itself describes something specific and understandable, and once you can picture what it means, the rest of your child's diagnosis starts to make more sense.
This guide breaks down what SCN2A haploinsufficiency is, how it affects the brain, what symptoms families commonly see, and where research is heading. It is written for caregivers — not for clinicians or scientists — though we have grounded every explanation in the current medical literature.
Every person inherits two copies of most genes — one from each biological parent. Haploinsufficiency is a genetic term meaning that one of those two copies is not working properly, and the single working copy alone is not enough to carry out the gene's full job.
In SCN2A haploinsufficiency, a child is born with one normally functioning copy of the SCN2A gene and a second copy that does not fully function as expected. In practical terms, this means children typically produce substantially reduced functional Nav1.2 protein, often approximating the effect of having only one working copy of the gene. The exact amount can vary depending on the specific variant, but the result is similar: less Nav1.2 than the brain expects.
This is why doctors and researchers sometimes call SCN2A haploinsufficiency a dosage problem. In many cases, the remaining copy functions relatively normally on its own, but the total amount of Nav1.2 produced is still insufficient for typical brain development and signaling.
The SCN2A gene gives the body the instructions to build a protein called Nav1.2 — a voltage-gated sodium channel. Sodium channels are tiny gates on the surface of brain cells that open and close to let charged particles flow in and out. That flow is how brain cells generate the electrical signals they use to talk to one another.
Nav1.2 is especially important early in life. In the first years of brain development, it helps young excitatory neurons fire properly and form connections. As development progresses, a related channel called Nav1.6 becomes increasingly important at the axon initial segment for sustaining high-frequency firing — but Nav1.2 continues to play a critical role in the dendrites, the branch-like structures where neurons receive signals from other cells. That ongoing dendritic role is one reason SCN2A is essential at every stage of life, not just infancy.
These two terms are closely related and often appear together in genetic reports, which can be confusing.
- Loss-of-function (LOF) describes what a mutation does to the channel — it reduces or eliminates how well that channel works.
- Haploinsufficiency describes the consequence — having only one functional copy is not enough for normal brain function.
Most cases of SCN2A haploinsufficiency are caused by loss-of-function mutations, including protein-truncating variants that prevent one copy of the gene from making a working channel at all. So while every haploinsufficiency case is a loss-of-function situation, not every loss-of-function variant produces classic haploinsufficiency. Some LOF variants make a partially working channel rather than no channel at all.
This distinction matters because SCN2A variants are generally grouped into three functional categories: gain-of-function (GOF), loss-of-function (LOF), and mixed function. SCN2A haploinsufficiency is generally considered part of the loss-of-function spectrum. The mutation type matters enormously for symptoms, prognosis, and especially treatment.
With substantially reduced Nav1.2 function available, certain brain cells — particularly excitatory pyramidal neurons in the cortex — cannot fire and integrate signals as efficiently as they should. Research published in Nature in 2025 by the laboratories of Kevin Bender and Nadav Ahituv at UCSF described how this reduction disrupts both the ability of these neurons to fire properly and the connections they form with their neighbors.
In simpler terms: the wiring of the brain is built and tuned through experience, and Nav1.2 helps neurons participate in that tuning. When the protein is reduced, those connections form less reliably, and the brain has a harder time learning to process information the way it typically would.
SCN2A haploinsufficiency can look very different from one child to the next. Some children have a strong autism profile with no seizures; others develop epilepsy, often later in infancy or childhood; some have significant intellectual disability while others have milder learning differences. Reviews in Brain and Genetics in Medicine emphasize that this variability is the rule, not the exception.
Many children with SCN2A haploinsufficiency are diagnosed with autism spectrum disorder (ASD), intellectual disability, or global developmental delay. SCN2A is considered one of the highest-confidence neurodevelopmental and autism-associated genes identified through large-scale exome sequencing studies.
Speech and language delays, social communication differences, sensory processing differences, and challenges with flexible thinking and decision-making are commonly reported by families and described in the clinical literature.
When seizures occur in children with loss-of-function SCN2A variants, they typically begin after the first three months of life — often in later infancy or childhood. This is in contrast to gain-of-function SCN2A variants, which usually cause seizures within the first weeks after birth. Some children with SCN2A haploinsufficiency never develop seizures at all.
Families and clinicians have described additional features in some children, including low muscle tone (hypotonia), coordination challenges, sensory hypersensitivity, sleep disruption, and gastrointestinal issues. These are not universal — every child's profile is different — but they are part of the broader picture clinicians watch for.
SCN2A haploinsufficiency is diagnosed through genetic testing — typically a panel for epilepsy or neurodevelopmental disorders, whole exome sequencing, or whole genome sequencing. The test report will name the specific variant found in SCN2A and usually classify it (for example, as a protein-truncating or loss-of-function variant).
The vast majority of SCN2A variants causing haploinsufficiency are de novo, meaning they arose newly in the child and were not inherited from either parent. This is something many families need to hear explicitly, because parental guilt is common and unwarranted. A de novo mutation is no one's fault — it is not the result of anything a parent did or did not do during pregnancy, and it does not reflect family history. Genetic counselors can be a valuable resource for understanding what a specific variant means for your family.
If you want to connect with other families navigating a similar diagnosis or contribute to natural history data, you can join the SCN2A community through the SCN2A Foundation.
Knowing whether a child's SCN2A variant causes loss of function (including haploinsufficiency), gain of function, or mixed function is one of the most important pieces of information a treating neurologist can have. The same gene can drive very different conditions depending on how the channel is affected, and the right treatment direction can differ accordingly.
Sodium channel blockers are a class of seizure medications that reduce sodium channel activity. For children with gain-of-function SCN2A variants — where the channel is overactive — these medications can be very helpful. For children with loss-of-function variants and SCN2A haploinsufficiency, the channel is already underactive, and blocking it further may worsen symptoms or provide limited benefit in some individuals — though treatment responses can vary significantly depending on circuitry, the specific epilepsy phenotype, and developmental timing.
This is not a decision for families to navigate alone. All seizure medication decisions should be made with a neurologist experienced in SCN2A-related disorders, ideally with the genetic test report in hand.
Because haploinsufficiency is fundamentally a dosage problem, it is also a particularly attractive target for new precision therapies. The therapeutic logic is straightforward: if there is one healthy gene copy already in place, the goal is to help that copy work harder — bringing the total amount of Nav1.2 protein closer to normal levels.
In September 2025, researchers led by Tamura, Nelson, and Spratt at UCSF — under the labs of Kevin Bender and Nadav Ahituv — published a landmark study in Nature demonstrating that CRISPR activation (CRISPRa) — a gene-editing tool that turns up the volume on existing genes without altering DNA — could rescue several disease-related deficits in mouse models of SCN2A haploinsufficiency. Importantly, the rescue worked even when treatment was given in adolescent mice, though it remains unknown how these findings will translate to human developmental windows. The study also showed CRISPRa rescued excitability in human stem-cell-derived neurons.
This work is preclinical — it has not yet been tested in humans, and the path from a mouse study to an approved therapy is long and uncertain. But it represents one of the strongest signals yet that SCN2A haploinsufficiency may be addressable at its root cause. You can follow the latest SCN2A research and emerging therapeutic pipelines through the Foundation's research updates.
A diagnosis of SCN2A haploinsufficiency does not define your child, and it does not write the ending to their story. Children with this condition are growing, learning, and surprising the people around them every day, and the science aimed at changing what is possible for them is moving faster now than at any point in the past.
Every family navigating an SCN2A diagnosis deserves answers, community, and continued progress. Continued research progress depends on sustained community support, advocacy, and funding. You can help by joining the SCN2A patient registry to add your child's data to the natural history record, and by making a donation to fund the research and resources that move this work forward.
This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Tamura S, Nelson AD, Spratt PWE, et al. CRISPR activation for SCN2A-related neurodevelopmental disorders. Nature. 2025;646(8086):983–991. Published online September 17, 2025. doi:10.1038/s41586-025-09522-w. https://www.nature.com/articles/s41586-025-09522-w
Berg AT, Thompson CH, Myers LS, et al. Expanded clinical phenotype spectrum correlates with variant function in SCN2A-related disorders. Brain. 2024;147(8):2761–2774. doi:10.1093/brain/awae125. https://academic.oup.com/brain/article/147/8/2761/7656659
Crawford K, Xian J, Helbig KL, et al. Computational analysis of 10,860 phenotypic annotations in individuals with SCN2A-related disorders. Genetics in Medicine. 2021. https://www.nature.com/articles/s41436-021-01120-1
Wolff M, Brunklaus A, Zuberi SM. Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond. Epilepsia. 2019;60(S3):S59–S67. https://onlinelibrary.wiley.com/doi/10.1111/epi.16336
Simons Searchlight. SCN2A-Related Syndrome Gene Guide. https://www.simonssearchlight.org/gene-guide/scn2a-2/
UCSF News. Can CRISPR Fix a Childhood Brain Disorder? September 2025. https://www.ucsf.edu/news/2025/09/430716/can-crispr-fix-childhood-brain-disorder
OMIM. SCN2A — Sodium Channel, Voltage-Gated, Type II, Alpha Subunit. https://www.omim.org/entry/182390
Spratt PWE, Ben-Shalom R, Keeshen CM, et al. The autism-associated gene Scn2a contributes to dendritic excitability and synaptic function in the prefrontal cortex. Neuron. 2019;103(4):673–685. https://pubmed.ncbi.nlm.nih.gov/31230762/
Vlad Magdalin
